4

Rare Diseases: Regulatory Incentives for Development of Orphan Drugs – The United States & Europe

Rare disease regulatory incentives for orphan drug development US EU

Many regulatory agencies across the world are offering incentives for the development of orphan drugs for rare diseases. These incentives include financial benefits, faster approvals, less stringent clinical data requirements, and many more. The countries that are offering the regulatory incentives for orphan drugs include the US, Europe, Japan, Australia, South Korea, Brazil, and most […]

Read More →
4

Clinical Trial Logistics – Rare Disease Clinical Trials

Clinical Trial Logistics - Rare Disease Clinical Trials

Clinical supply chain teams manage some typical challenges almost every day of their work in handling clinical trial logistics for local or global clinical trials. These include those related to regulatory compliance, temperature control (or, excursions), labeling, actual shipment, or last-mile delivery. These challenges are often compounded multi-fold when clinical trials are related to a […]

Read More →
0

Understanding Global Regulatory Pathways For Clinical Development Strategy

Learning about global regulatory requirements and understanding the pathway for approval can help clinical development teams take their global strategy in the right direction. Sharing expertise from regulatory experts for those who need it. (This article was originally published on LinkedIn). It’s no news that we are now living in an era with a tremendous surge […]

Read More →
1

This is the primary challenge in Rare Disease Clinical Trials – And, a ready solution is available

Rare diseases are rapidly becoming a high priority therapeutic area for our industry. This is needed, especially when fewer than 5% of approx 7,000 rare diseases have drug therapies available, and many of these provide limited benefit. There is also a business case to this, due to a supportive reimbursement environment, particularly in the US. […]

Read More →
0

Rare diseases: Drug development strategy

drug development strategy in rare diseases

Rare disease drug development is gaining interest in the pharma industry. Large pharmaceutical companies have been working for many years. Now, startups, and small and mid-range pharma companies are also gaining traction in rare disease drug development.  Developing medicines or drug products for rare diseases is always challenging. This applies to both the scientific and […]

Read More →
0

What You Need to Know to Register Nutraceutical, Dietary, Or Food Supplement Products In Europe – Part II

Nutraceuticals or Health supplements are gaining importance and becoming a part of the consumer’s daily diet. With the increase in life expectancy and subsequent increase in lifestyle-related diseases, nutraceutical or health supplements have emerged as a necessity for consumers, especially in a developed market and Europe is not an exception to it! Novel food represents […]

Read More →
0

How can small-mid scale bio-pharma fast track their clinical development & product registration processes? Leveraging secrets of a global network

Credevo Global Network for Clinical Development and Product Registrations

Cost and time for clinical development constitute more than 70% of the total development of any drug! Small – mid-scale biopharma are known for their innovative approaches, agility, and faster developments. However, clinical development has always been one step too important, yet too hard for them. There are ways to overcome these challenges and optimize […]

Read More →
0

How To Choose a CRO?: Small and Mid-Size Pharma Companies

CRO (Contract Research Organizations) for small and mid size pharma

Most of the small and mid-size pharma are stressed out while outsourcing pre-clinical and clinical development to CRO (Contract Research Organization). Selection factors differ while choosing CRO for large and small-medium scale companies. These include factors like budgeting, multiple region selection, and approaches. Increased outsourcing is seen in pharmaceutical and biotechnology companies, with 85 percent of […]

Read More →
0

Rare Diseases: Patient Recruitment Strategies in Clinical Trials

patient recruitment in rare disease clinical trials

Patient recruitment in rare disease clinical trials presents several difficulties. These challenges include limited eligible patients, dispersed geographic distribution, low disease awareness, site and investigator identification difficulties, and ethical considerations. They hinder participant enrollment and cause trial completion delays. Over the past few years, the rate of drug development in rare diseases has been increasing. […]

Read More →